Help
Posted Fri, Jan, 25,2013
Published today in Clinical Medicine Insights: Therapeutics is a new review by Donal P. McLornan, John Laurie and Claire N. Harrison. Read more about this paper below:
Title:
Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib
Abstract:
In November 2011, the United States Food and Drug Administration (FDA) approved the use of a novel Janus Kinase (JAK) 1/JAK2 inhibitor, INCB 018424 (ruxolitinib), for use in both intermediate and high risk myelofibrosis. Approvals of this agent in both Canada and Europe have followed most recently. The European Medicines Agency (EMA) concluded that ruxolitinib was indicated for disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera (PV) myelofibrosis, and post-essential thrombocythaemia (ET) myelofibrosis. In this review we will consider the rationale for targeting of the JAK-pathway, discuss the pharmacological profile of ruxolitinib and review the currently available clinical trial data. We will also postulate on the current and potential future roles of ruxolitinib within the MPN field.
Click here to learn more about the article, download it and comment
Posted in: Articles Published
News Categories
Thu 08 Oct, 2015
Published This Week (5th - 9th October)Thu 08 Oct, 2015
Biomarker Insights Paper Endorsed by Editor in ChiefWed 07 Oct, 2015
Interview with Professor Jamie DaviesMy experience with Libertas Academica was an extremely positive, satisfying and rewarding one. The process was exceptionally smooth, the author interface unusually user-friendly, and the editorial team unbelievably supportive. Overall, I thoroughly enjoyed my publishing experience with Libertas Academica and would gladly welcome the opportunity to publish with them again. Thank you for such a painless and gratifying publication process!
Facebook Google+ Twitter
Pinterest Tumblr YouTube